VistaGen Therapeutics (NASDAQ:VTGN) Lowered to Hold at Zacks Investment Research

VistaGen Therapeutics (NASDAQ:VTGN) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday, Zacks.com reports.

According to Zacks, “VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company’s lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. “

Separately, Robert W. Baird reaffirmed a “buy” rating and set a $9.00 target price on shares of VistaGen Therapeutics in a research report on Sunday, August 15th.

VTGN stock traded up $0.02 during trading on Thursday, hitting $2.51. The company had a trading volume of 2,614 shares, compared to its average volume of 2,518,249. The business has a 50-day moving average of $2.83 and a 200-day moving average of $2.67. VistaGen Therapeutics has a one year low of $0.61 and a one year high of $3.55. The stock has a market cap of $484.19 million, a PE ratio of -6.97 and a beta of 0.92.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Thursday, August 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The firm had revenue of $0.35 million for the quarter, compared to analysts’ expectations of $0.37 million. VistaGen Therapeutics had a negative return on equity of 32.73% and a negative net margin of 1,561.84%. Equities analysts expect that VistaGen Therapeutics will post -0.22 earnings per share for the current fiscal year.

In other news, CFO Jerrold Duane Dotson sold 30,000 shares of the stock in a transaction on Tuesday, September 7th. The stock was sold at an average price of $3.12, for a total transaction of $93,600.00. Following the completion of the transaction, the chief financial officer now owns 72,786 shares in the company, valued at approximately $227,092.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.67% of the stock is currently owned by corporate insiders.

Several hedge funds have recently bought and sold shares of VTGN. Xponance Inc. bought a new position in VistaGen Therapeutics in the 2nd quarter worth about $33,000. Blair William & Co. IL bought a new position in VistaGen Therapeutics in the 2nd quarter worth about $38,000. Parametric Portfolio Associates LLC bought a new position in VistaGen Therapeutics in the 2nd quarter worth about $38,000. Prudential Financial Inc. bought a new position in VistaGen Therapeutics in the 2nd quarter worth about $39,000. Finally, Atom Investors LP bought a new position in VistaGen Therapeutics in the 1st quarter worth about $41,000. Institutional investors own 64.04% of the company’s stock.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc is a clinical-stage biopharmaceutical company committed to developing and commercializing new generation medications that go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders. The company’s portfolio includes PH94B, a neuroactive nasal spray with potential to treat multiple anxiety disorders that the company is currently preparing for phase III clinical trial for social anxiety disorder (SAD); PH10, a neuroactive nasal spray that the company is planning for phase 2b development as a stand-alone treatment for major depressive disorder (MDD); and AV-101 which the company is developing for the treatment of major depressive disorder (MDD), suicidal ideation, neuropathic pain, levodopa-induced dyskinesia (LID), and epilepsy.

See Also: What does a dividend yield signify to investors?

Get a free copy of the Zacks research report on VistaGen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for VistaGen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VistaGen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.